By Reuters Staff
August 22, 2019
NEW YORK (Reuters Health) - The direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir is effective in patients with genotype 1 hepatitis C virus (HCV) infection after failure of treatment with sofosbuvir plus an NS5A inhibitor, according to results from a new open-label trial.
The combination of ...
Map of Hepatitis C in Asia
Latest Stories from Patient
My Name is Ayu Oktariani, I’m from Bandung, Indonesia, I am 29 years old female. I’m co-infection HIV HCV patient, since 2009. My HIV condition is very well managed since the time infected, the ARV therapy help me through the … Read More
My name is Ajitshwor Wangkheirakpam. I am 42 years old male from Manipur in India. I have been living with HIV and HCV co-infection for a long time. My HIV have been completely well controlled and managed, thanks to the … Read More